These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 18660730)

  • 21. Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction.
    Frishman WH; Henderson LS; Lukas MA
    Vasc Health Risk Manag; 2008; 4(6):1387-400. PubMed ID: 19337551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antihypertensive treatment with a dual-acting beta-blocker in the elderly.
    Lessem JN; Weber MA
    J Hypertens Suppl; 1993 Jun; 11(4):S29-36. PubMed ID: 8104239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of vasodilating beta-blockers on cardiac function and vascular resistance in essential hypertension.
    Lund-Johansen P
    Clin Nephrol; 1992; 38 Suppl 1():S78-86. PubMed ID: 1363538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy.
    Sica DA; Black HR
    Curr Hypertens Rep; 2008 Aug; 10(4):330-5. PubMed ID: 18625165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical experience with carvedilol.
    Moser M
    J Hum Hypertens; 1993 Feb; 7 Suppl 1():S16-20. PubMed ID: 8098064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Practical considerations for switching beta-blockers in heart failure patients.
    Abraham WT; Iyengar S
    Rev Cardiovasc Med; 2004; 5 Suppl 1():S36-44. PubMed ID: 15184837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic properties of a new controlled-release formulation of carvedilol.
    Tenero DM; Henderson LS; Baidoo CA; Harter AH; Campanile AM; Danoff TM; Boyle D
    Am J Cardiol; 2006 Oct; 98(7A):5L-16L. PubMed ID: 17023227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What is the role, if any, for beta-blockers as initial therapy for uncomplicated hypertension?
    Pedersen ME; Cockcroft JR
    Curr Opin Cardiol; 2009 Jul; 24(4):325-32. PubMed ID: 19417638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol.
    Breckenridge A; Roberts DH
    J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S78-81. PubMed ID: 1721985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review.
    Carella AM; Antonucci G; Conte M; Di Pumpo M; Giancola A; Antonucci E
    Curr Diabetes Rev; 2010 Jul; 6(4):215-21. PubMed ID: 20459394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol.
    Fonarow GC
    Expert Opin Pharmacother; 2006 Dec; 7(18):2533-46. PubMed ID: 17150007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of multiple action agents in hypertension.
    Lund-Johansen P; Omvik P
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S89-95. PubMed ID: 1974512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progression from hypertension to heart failure. Mechanisms and management.
    Cleland JG
    Cardiology; 1999; 92 Suppl 1():10-9; discussion 20-1. PubMed ID: 10652967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal use of beta-blockers in high-risk hypertension: a guide to dosing equivalence.
    McGill JB
    Vasc Health Risk Manag; 2010 Jun; 6():363-72. PubMed ID: 20539838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of Beta-blockers as first-line therapy in hypertension.
    De Caterina AR; Leone AM
    Curr Atheroscler Rep; 2011 Apr; 13(2):147-53. PubMed ID: 21207202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypertension and coronary artery disease: a therapeutic challenge.
    Taylor SH
    J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S39-44. PubMed ID: 1721978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching between beta blockers in heart failure patients: rationale and practical considerations.
    Abraham WT
    Congest Heart Fail; 2003; 9(5):271-8. PubMed ID: 14564146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carvedilol for hypertension.
    Drug Ther Bull; 1995 May; 33(5):39-40. PubMed ID: 7587995
    [No Abstract]   [Full Text] [Related]  

  • 39. Appropriate dose transition to a controlled-release formulation of carvedilol in patients with hypertension.
    Bakris GL; Weber MA
    Rev Cardiovasc Med; 2008; 9(2):96-105. PubMed ID: 18660730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carvedilol versus cardioselective beta-blockers for the treatment of hypertension in patients with type 2 diabetes mellitus.
    Fardoun RZ
    Pharmacotherapy; 2006 Oct; 26(10):1491-500. PubMed ID: 16999659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.